Cyromazine

As a broad-spectrum insect growth regulator API, cyromazine interferes with the molting and reproduction processes of insects by inhibiting chitin synthesis, and has dual effects of gastric toxicity and contact toxicity. In the field of veterinary medicine, it is mainly used to prevent and treat ectoparasitic infections such as sarcoptes scabiei, psoroptes, ticks and fly maggots in livestock such as cattle and sheep, and can also be used for the prevention and control of vector organisms such as mosquitoes and flies in the public health field. It is currently one of the core varieties with high safety and slow occurrence of drug resistance in the global parasite prevention and control system for livestock breeding, and is of great value for reducing the spread of livestock parasitic diseases and improving the economic benefits of breeding.

According to public industry data, the global cyromazine market size was approximately USD 127 million in 2023, and the compound annual growth rate from 2024 to 2030 is expected to remain at around 5.2%. The growth momentum mainly comes from the improvement of the scale rate of global livestock breeding and the continuous release of demand for environmentally friendly insecticides in the public health field. In the current global supply pattern, Chinese enterprises account for more than 60% of the global API production capacity, making China the most important producer and exporter; in terms of the domestic market, with the advancement of the veterinary drug antibiotic reduction policy, the market penetration rate of cyromazine as a low-toxicity antiparasitic drug is increasing year by year. At present, more than 10 enterprises have obtained the production approval numbers for veterinary APIs, and the industry competition is relatively sufficient.

The original developer of cyromazine is Novartis, Switzerland, with the original brand name "Cyromazine", and its core compound patent expired globally in 1999. At present, the mainstream marketed dosage forms in the world include wettable powder, emulsifiable concentrate, soluble powder, etc. The common specifications for veterinary drugs include 1%, 50%, 75%, etc., and cyromazine has been included in the FDA Reference Listed Drug Catalog for Animal Drugs. In China, as of now, more than 30 cyromazine APIs have been approved for marketing by the CDE (including the veterinary drug approval channel), and a number of related preparation varieties have been approved for use in the field of livestock parasite prevention and control. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of cyromazine impurity reference standards. Most of the products are available in stock, and stock orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the needs of API enterprises in various scenarios such as quality research, impurity analysis, registration and declaration.